236 related articles for article (PubMed ID: 17785319)
21. Exercise paradoxically modulates oxidized low density lipoprotein-induced adhesion molecules expression and trans-endothelial migration of monocyte in men.
Wang JS; Chen YW; Chow SE; Ou HC; Sheu WH
Thromb Haemost; 2005 Oct; 94(4):846-52. PubMed ID: 16270641
[TBL] [Abstract][Full Text] [Related]
22. β2-glycoprotein I and oxidative inflammation in early atherogenesis: a progression from innate to adaptive immunity?
Matsuura E; Lopez LR; Shoenfeld Y; Ames PR
Autoimmun Rev; 2012 Dec; 12(2):241-9. PubMed ID: 22569463
[TBL] [Abstract][Full Text] [Related]
23. Dynamic determination of Ox-LDL-induced oxidative/nitrosative stress in single macrophage by using fluorescent probes.
Deng T; Xu K; Zhang L; Zheng X
Cell Biol Int; 2008 Nov; 32(11):1425-32. PubMed ID: 18782627
[TBL] [Abstract][Full Text] [Related]
24. Patients with atherosclerotic syndrome, negative in anti-cardiolipin assays, make IgA autoantibodies that preferentially target domain 4 of beta2-GPI.
Iverson GM; von Mühlen CA; Staub HL; Lassen AJ; Binder W; Norman GL
J Autoimmun; 2006 Dec; 27(4):266-71. PubMed ID: 17081732
[TBL] [Abstract][Full Text] [Related]
25. Immunogenic oxidized low-density lipoprotein/beta2-glycoprotein I complexes in the diagnostic management of atherosclerosis.
Lopez LR; Kobayashi K; Matsunami Y; Matsuura E
Clin Rev Allergy Immunol; 2009 Aug; 37(1):12-9. PubMed ID: 18982458
[TBL] [Abstract][Full Text] [Related]
26. The involvement of beta2-glycoprotein I (beta2-GPI) in human and murine atherosclerosis.
George J; Shoenfeld Y; Harats D
J Autoimmun; 1999 Aug; 13(1):57-60. PubMed ID: 10441168
[TBL] [Abstract][Full Text] [Related]
27. Elevated beta2-glycoprotein I-low-density lipoprotein levels are associated with the presence of diabetic microvascular complications.
Yu R; Yuan Y; Niu D; Song J; Liu T; Wu J; Wang J
J Diabetes Complications; 2015; 29(1):59-63. PubMed ID: 25449980
[TBL] [Abstract][Full Text] [Related]
28. Antibodies to oxidized low density lipoprotein: epidemiological studies and potential clinical applications in cardiovascular disease.
Gounopoulos P; Merki E; Hansen LF; Choi SH; Tsimikas S
Minerva Cardioangiol; 2007 Dec; 55(6):821-37. PubMed ID: 18091649
[TBL] [Abstract][Full Text] [Related]
29. Recombinant domain V of β2-glycoprotein I inhibits the formation of atherogenic oxLDL/β2-glycoprotein I complexes.
Li J; Chi Y; Liu S; Wang L; Wang R; Han X; Matsuura E; Liu Q
J Clin Immunol; 2014 Aug; 34(6):669-76. PubMed ID: 24970589
[TBL] [Abstract][Full Text] [Related]
30. The in vitro effect of oxidized LDL and PHA on proliferation and gene expression of regulatory T cells in patients with atherosclerosis.
Mottaghi A; Salehi E; Sezavar H; Keshavarz SA; Eshraghian MR; Rezaei N; Rejali L; Saboor-Yaraghi AA
Iran J Allergy Asthma Immunol; 2012 Sep; 11(3):217-23. PubMed ID: 22947906
[TBL] [Abstract][Full Text] [Related]
31. Antibodies to oxidized LDL/beta2-glycoprotein I in antiphospholipid syndrome patients with venous and arterial thromboembolism.
Pengo V; Bison E; Ruffatti A; Iliceto S
Thromb Res; 2008; 122(4):556-9. PubMed ID: 18328538
[TBL] [Abstract][Full Text] [Related]
32. Concentration polarization of oxidative modification of low-density lipoproteins: its effect on oxidative modification of low-density lipoprotein uptake and apoptosis of the endothelial cells.
Ding Z; Fan Y; Deng X
ASAIO J; 2010; 56(5):468-74. PubMed ID: 20616702
[TBL] [Abstract][Full Text] [Related]
33. Impact of plasma oxidized low-density lipoprotein removal on atherosclerosis.
Ishigaki Y; Katagiri H; Gao J; Yamada T; Imai J; Uno K; Hasegawa Y; Kaneko K; Ogihara T; Ishihara H; Sato Y; Takikawa K; Nishimichi N; Matsuda H; Sawamura T; Oka Y
Circulation; 2008 Jul; 118(1):75-83. PubMed ID: 18559699
[TBL] [Abstract][Full Text] [Related]
34. Beta2-glycoprotein I binds thrombin via exosite I and exosite II: anti-beta2-glycoprotein I antibodies potentiate the inhibitory effect of beta2-glycoprotein I on thrombin-mediated factor XIa generation.
Rahgozar S; Yang Q; Giannakopoulos B; Yan X; Miyakis S; Krilis SA
Arthritis Rheum; 2007 Feb; 56(2):605-13. PubMed ID: 17265495
[TBL] [Abstract][Full Text] [Related]
35. Atherosclerosis in autoimmune diseases.
Matsuura E; Kobayashi K; Lopez LR
Curr Rheumatol Rep; 2009 Feb; 11(1):61-9. PubMed ID: 19171113
[TBL] [Abstract][Full Text] [Related]
36. Preventing autoimmune and infection triggered atherosclerosis for an enduring healthful lifestyle.
Matsuura E; Kobayashi K; Lopez LR
Autoimmun Rev; 2008 Jan; 7(3):214-22. PubMed ID: 18190881
[TBL] [Abstract][Full Text] [Related]
37. Potential protective role of apoprotein J (clusterin) in atherogenesis: binding to enzymatically modified low-density lipoprotein reduces fatty acid-mediated cytotoxicity.
Schwarz M; Spath L; Lux CA; Paprotka K; Torzewski M; Dersch K; Koch-Brandt C; Husmann M; Bhakdi S
Thromb Haemost; 2008 Jul; 100(1):110-8. PubMed ID: 18612545
[TBL] [Abstract][Full Text] [Related]
38. The immunology of atherothrombosis in the antiphospholipid syndrome: antigen presentation and lipid intracellular accumulation.
Matsuura E; Kobayashi K; Matsunami Y; Lopez LR
Autoimmun Rev; 2009 May; 8(6):500-5. PubMed ID: 19171205
[TBL] [Abstract][Full Text] [Related]
39. Humoral mechanisms of atherogenesis.
Batuca JR; Amaral MC; Alves JD
Ann N Y Acad Sci; 2009 Sep; 1173():401-8. PubMed ID: 19758179
[TBL] [Abstract][Full Text] [Related]
40. Oxidation of LDL and its clinical implication.
Matsuura E; Hughes GR; Khamashta MA
Autoimmun Rev; 2008 Jul; 7(7):558-66. PubMed ID: 18625445
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
